ArticleJournal of gastrointestinal oncology2024
High expression of RBM15 is associated with better prognosis in esophageal squamous cell carcinoma.
Article in Journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- RBM3-associated germline variants and their functional role in gastric cancer susceptibility and progression.Frontiers in oncology · 2026Article
- RNA-binding motif proteins as context-dependent regulators of tumor-immune crosstalk, genome stability, and therapeutic vulnerabilities in cancer.Frontiers in immunology · 2026Review
- Camrelizumab combined with neoadjuvant docetaxel, oxaliplatin, and S1 as induction therapy for locally advanced esophageal squamous cell cancer: a real-world single-center cohort study.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is a highly prevalent and malignant form of esophageal tumor associated with high rates of patient mortality for which there remains a persistent lack of effective targets for therapeutic interventional efforts. This study was developed with the goal of exploring the expression and functional role of RBM15 in ESCC. Methods: This study was developed with the goal of exploring the expression and functional role of RBM15 in ESCC. To establish the prognostic and therapeutic significance of RBM15 in this cancer, data from the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and UCSC Xena databases were leveraged. Immunohistochemical analyses were used to assess RBM15 expression in postoperative ESCC tumor tissue samples, and the correlations between such expression and patient outcomes were assessed. The effects of RBM15 on ESCC cell proliferative, migratory, and invasive activity were assessed with Cell Counting Kit-8 (CCK8) and Transwell assay approaches. Together, these experiments revealed RBM15 upregulation in ESCC relative to paracancerous tissues, while confirming that it was associated with favorable patient outcomes. RBM15 was also found to suppress ESCC cell proliferation, migration, and invasivity. Results: We suggest that RBM15 may be a clinically relevant prognostic factor in ESCC such that new therapeutic interventions based on low levels of RBM15 have the potential to be developed for the improved management of ESCC in the future. Conclusions: The results of the present study provide confirmation that high levels of RBM15 expression are protective and associated with better ESCC patient prognostic outcomes. Pan-cancer analyses performed herein also revealed the correlations between RBM15 expression and prognosis in various cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.